Remus Pharmaceuticals
add_icon

Remus Pharmaceuticals

650.30
+2.95
(0.46%)
Market Cap
766.31 Cr
PE Ratio
19.86
Volume
2,700.00
Day High - Low
658.90 - 635.00
52W High-Low
2,290.00 - 580.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
766.31 Cr
EPS
65.21
PE Ratio
19.86
PB Ratio
2.98
Book Value
217.13
EBITDA
50.70
Dividend Yield
0.12 %
Industry
Healthcare
Return on Equity
13.60
Debt to Equity
0.09
Forecast For
Actual

Company News

View All News
Caret
positive
Remus Pharmaceuticals reported H1 consolidated net profit of 175 million rupees compared to 131 million rupees in the same period last year. Revenue increased to 4 billion rupees from 2.72 billion rupees year-over-year. EBITDA rose to 269 million rupees from 211 million rupees, though EBITDA margin declined to 6.7% from 7.8% in the previous year.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,777.10
#1 4,26,385.82
38.21
#1 54,729.00
9.71
#1 10,980
16.07
53.49
6,100.00
1,61,935.83
64.01
9,712.00
18.67
2,191
-1.02
43.80
4,270.20
1,44,522.97
62.70
11,539.40
6.99
1,911
26.24
50.03
1,298.90
1,08,410.14
19.25
33,741.20
16.73
5,725
-15.28
53.38
2,322.50
1,06,091.52
22.06
22,909.50
13.74
3,306
#1 37.44
56.84
1,256.40
1,01,488.45
22.07
28,409.50
7.12
5,291
-57.18
31.85
890.50
89,605.14
#1 17.54
23,511.00
18.55
4,615
-0.32
45.58
2,000.00
82,561.01
45.82
12,744.20
#1 20.90
2,007
7.65
37.22
1,291.40
75,004.72
20.80
32,345.60
9.43
3,484
7.59
60.75
5,257.50
62,861.30
25.87
13,458.30
3.70
2,216
1.90
37.74
Growth Rate
Revenue Growth
189.76 %
Net Income Growth
58.02 %
Cash Flow Change
417.78 %
ROE
-1.88 %
ROCE
-1.75 %
EBITDA Margin (Avg.)
-45.01 %

Yearly Financial Results

Annual Financials
2024
2025
TTM
Revenue
216
625
0
Expenses
184
575
0
EBITDA
32
51
0
Operating Profit %
14 %
7 %
0 %
Depreciation
1
2
0
Interest
1
2
0
Profit Before Tax
30
47
0
Tax
6
9
0
Net Profit
24
38
0
EPS in ₹
42.97
65.21
0.00

Balance Sheet

Balance Sheet
2024
2025
Total Assets
333
433
Fixed Assets
14
16
Current Assets
212
221
Capital Work in Progress
0
0
Investments
105
186
Other Assets
215
231
Total Equity & Liabilities
333
433
Current Liabilities
141
122
Non Current Liabilities
17
29
Total Equity
175
283
Reserve & Surplus
156
250
Share Capital
2
6

Cash Flow

Cash Flow
2024
2025
Net Cash Flow
4
3
Investing Activities
-25
-11
Operating Activities
1
7
Financing Activities
28
6

Share Holding

% Holding
Mar 2023
May 2023
Sept 2023
Mar 2024
Jun 2024
Sept 2024
Mar 2025
Jul 2025
Sept 2025
Promoter
92.82 %
68.37 %
69.61 %
70.60 %
70.66 %
70.84 %
70.85 %
70.85 %
70.91 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.92 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
6.44 %
16.69 %
21.15 %
20.54 %
20.90 %
20.49 %
19.18 %
18.90 %
18.78 %
Others
0.74 %
14.02 %
9.24 %
8.85 %
8.44 %
8.67 %
9.97 %
10.25 %
10.32 %
No of Share Holders
30
1,743
856
1,124
1,577
1,753
398
2,017
2,032

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 2 6 1.5 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.27 0.23 0.00

Technical Indicators

RSI(14)
Neutral
48.54
ATR(14)
Less Volatile
40.45
STOCH(9,6)
Neutral
55.28
STOCH RSI(14)
Neutral
73.08
MACD(12,26)
Bullish
5.17
ADX(14)
Weak Trend
16.92
UO(9)
Bearish
49.54
ROC(12)
Uptrend And Accelerating
6.58
WillR(14)
Neutral
-59.18